Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

Minke He(Sun Yat-sen University), Ming Shi(Yanshan University), Ruhai Zou(Sun Yat-sen University), Yuan-Min Zhou(Twelfth Guangzhou City People's Hospital), JingXian Shen(Sun Yat-sen University), Li Xu(Jiangxi University of Traditional Chinese Medicine), Wanqiang Fang(Kaiping Central Hospital), Zhongguo Zhou(Sun Yat-sen University), Yong Le(Sun Yat-sen University), Ming Zhao(State Key Laboratory of Oncology in South China), MinShan Chen(Sun Yat-sen University), Wei Wei(Zhujiang Hospital), Guosheng Tan(Sun Yat-sen University), Xiaoping Wu(Central South University), QiJiong Li(Sun Yat-sen University), Ying Guo(Sun Yat-sen University), Rong Guo(Sun Yat-sen University)
JAMA Oncology
May 9, 2019
10.1001/jamaoncol.2019.0250
Cited by 559

Related Papers

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
|The Lancet|2021|234
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment
|JAMA|2020|229